A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

A Phase I, Open-Label Study to Investigate the Tolerability and Safety of IBI310 Alone or in Combination With Sintilimab in the Treatment of Patients With Advanced Solid Tumors.

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310, and in combination of sintilimab, in patients with advanced solid tumors(Ia) and advanced melanoma(Ib).

Study Overview

• Status: Completed
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Drug: IBI310; Drug: Sintilimab

Detailed Description

Phase Ia study will adopt the classical 3+3 dose escalation design. The starting dose is 0.3 mg/kg, followed by 3 dose cohorts (1mg/kg, 2mg/kg and 3mg/kg). Duration of dose limiting toxicity (DLT) observation period is 21 days. IBI310 treatment q3w, up to 3 cycles, will be provided to patients who complete DLT observation period.

Efficacy will primarily be evaluated by RECIST v1.1. Patient safety will be monitored throughout the study. Pharmacokinetic/pharmacodynamics and immunogenicity will be assessed throughout the study.

Phase Ib study will evaluate the tolerability and safety of IBI310 combined with Sintilimab in patients with advanced melanoma. Phase Ib of the study will begin after DLT observation is completed in certain dose cohorts.

• Study Type: Interventional
• Enrollment (Actual): 53
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China
      • Beijing Cancer Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

1. Patients with locally advanced, recurrent or metastatic solid tumors who failed standard treatment(applicable to the Ia period).
2. Patients with advanced, recurrent or metastatic melanoma confirmed by cytology or histology (applicable to the Ib period).
3. Signed written informed consent form and willing and able to comply with scheduled visits and other requirements of the study.
4. ≥18，and ≤70 years.
5. Life expectancy of at least 12 weeks.
6. At least 1 measurable lesion per RECIST v1.1(long axis>15mm or short axis>10mm)
7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1.
8. Patients of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study medication.
9. Adequate organ and bone marrow function.

Key Exclusion Criteria:

1. Prior exposure to any anti-CTLA-4, anti-PD-1 or anti-PD-L1/L2 antibody.
2. Received any investigational agent within 4 weeks of the first dose of study medication.
3. Received last dose of anti-tumor therapy (chemotherapy, endocrine therapy, targeted therapy, tumor immunotherapy or arterial embolization) within 4 weeks of the first dose of study medication.
4. Received treatment with corticosteroids (>10mg daily prednisone equivalent) or other immunosuppressive medications within 4 weeks before the first dose of study medication. Nasal spray, inhalation, or other ways of topical corticosteroids or physiological doses of systemic corticosteroids are not included.
5. Received a live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.
6. Active, known or suspected autoimmune disease or has a history of the disease within the last 2 years (Patients with vitiligo, psoriasis, alopecia or Grave's disease, hypothyroidism requiring hormone replacement, or type I diabetes mellitus only requiring insulin replacement, but not required systemic treatment in the last 2 years, are permitted to enroll)
7. Known primary immunodeficiency
8. Active tuberculosis
9. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation
10. Known allergy or hypersensitivity to any other monoclonal antibodies or IBI310 and/or any components used in their preparation.
11. Known acute or chronic active hepatitis B (HBV DNA positive and HBV DNA copies ≥1×103/ml or ≥200IU/ml) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection. Patients with HCV antibody positive but HCV RNA negative are permitted to enroll.
12. Patients with a history of interstitial lung disease
13. Uncontrolled third space effusion, eg. ascites or pleural effusion cannot be drained or controlled.
14. Women who are pregnant or nursing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ia Cohort A; Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.	Drug: IBI310; IBI310 is anti CTLA-4 antibody; Other Names: CTLA-4
Experimental: Ia Cohort B; Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity	Drug: IBI310; IBI310 is anti CTLA-4 antibody; Other Names: CTLA-4
Experimental: Ia Cohort C; Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity	Drug: IBI310; IBI310 is anti CTLA-4 antibody; Other Names: CTLA-4
Experimental: Ia Cohort D; High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity	Drug: IBI310; IBI310 is anti CTLA-4 antibody; Other Names: CTLA-4
Experimental: Ib Cohort A; 3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.	Drug: IBI310; IBI310 is anti CTLA-4 antibody; Other Names: CTLA-4; Drug: Sintilimab; PD-1 monoclonal antibody
Experimental: Ib Cohort A2; low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.	Drug: IBI310; IBI310 is anti CTLA-4 antibody; Other Names: CTLA-4; Drug: Sintilimab; PD-1 monoclonal antibody
Experimental: Ib Cohort B; 3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.	Drug: IBI310; IBI310 is anti CTLA-4 antibody; Other Names: CTLA-4; Drug: Sintilimab; PD-1 monoclonal antibody
Experimental: Ib Cohort B2; low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.	Drug: IBI310; IBI310 is anti CTLA-4 antibody; Other Names: CTLA-4; Drug: Sintilimab; PD-1 monoclonal antibody

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AEs	Number of patients with treatment-related adverse events (AEs)	up to 24 months after randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics：Cmax	Maximum concentration(Cmax) of the drug after administration	up to 24 months after randomization
pharmacodynamics:lipid parameters	Change from baseline in lipid parameters	up to 24 months after randomization
ADA	Number of participants with anti-drug antibodies or neutralizing antibodies	up to 24 months after randomization
Pharmacokinetics：AUC	The area under the curve (AUC) of serum concentration of the drug after the administration	up to 24 months after randomization

Collaborators and Investigators

• Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 25, 2018
• Primary Completion (Actual): September 10, 2021
• Study Completion (Actual): August 9, 2022

Study Registration Dates

• First Submitted: May 10, 2018
• First Submitted That Met QC Criteria: May 22, 2018
• First Posted (Actual): June 6, 2018

Study Record Updates

• Last Update Posted (Estimate): February 28, 2023
• Last Update Submitted That Met QC Criteria: February 24, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: CIBI310A101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No